Midterm Outcome of Femoral Artery Stenting and Factors Affecting Patency.
10.5758/vsi.2015.31.4.115
- Author:
Jae Seoung YU
1
;
Keun Myoung PARK
;
Yong Sun JEON
;
Soon Gu CHO
;
Kee Chun HONG
;
Woo Young SHIN
;
Yun Mee CHOE
;
Seok Hwan SHIN
;
Kyung Rae KIM
Author Information
1. Department of Surgery, Inha University College of Medicine, Incheon, Korea. redfrag@naver.com
- Publication Type:Original Article
- Keywords:
Femoral artery;
Peripheral arterial occlusive disease;
Stents;
Endovascular procedures
- MeSH:
Ankle Brachial Index;
Constriction, Pathologic;
Diabetes Mellitus;
Endovascular Procedures;
Extremities;
Femoral Artery*;
Follow-Up Studies;
Humans;
Stents*;
Tibial Arteries
- From:Vascular Specialist International
2015;31(4):115-119
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the early and midterm results of superficial femoral artery (SFA) stenting with self-expanding nitinol stents and to identify the factors affecting patency. MATERIALS AND METHODS: SFA stenting was performed in 165 limbs of 117 patients from January 2009 to December 2013. Patients were followed-up for the first occurrence of occlusion or stenosis based on computed tomography and duplex scan results and a decrease in ankle brachial index of >15%. RESULTS: During the follow-up period (mean, 15.3+/-3.2 months), no early thrombotic reocclusions occurred within 30 days, but in-stent restenosis developed in 78 limbs. The primary patency rates at 6, 12, 18, and 24 months were 78%, 66%, 42%, and 22%, respectively, and the secondary patency rates were 85%, 72%, 58%, and 58%, respectively. TASC II C or D lesions, stent length >8 cm, number of patent tibial arteries and diabetes were significantly associated with reintervention. CONCLUSION: The midterm results of stenting for SFA occlusive disease were disappointing because the primary and secondary patency rates at two years were 22% and 58%, respectively. Reintervention after SFA stenting remains a major problem, particularly in patients with diabetes mellitus or long TASC II C or D lesions.
